Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms - 14/03/19
Doi : 10.1016/j.jaad.2018.10.064
Deborah N. Dorrell, BA, Litton F. Whitaker, BS, Kathryn L. Anderson, MD, Lindsay C. Strowd, MD ⁎ 
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
∗Reprint requests: Lindsay Chaney Strowd, MD, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071Department of DermatologyWake Forest School of MedicineMedical Center BlvdWinston-SalemNC27157-1071
| Funding sources: None. |
|
| Disclosure: Dr Strowd is a speaker for Actelion, consultant for Galderma USA, advisory board member for Regeneron, and principal investigator for Pfizer Inc. Ms Dorrell, Ms Whitaker, and Dr Anderson have no conflicts of interest to disclose. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 4
P. 1159-1160 - avril 2019 Retour au numéro
Article précédent
- Trends in incidence of cutaneous malignant melanoma in Canada: 1992-2010 versus 2011-2015
- Feras M. Ghazawi, Michelle Le, Nebras Alghazawi, Elham Rahme, Linda Moreau, Elena Netchiporouk, Andrei Zubarev, Osama Roshdy, Steven J. Glassman, Denis Sasseville, Ivan V. Litvinov
- Initiation of methotrexate with or without a test dose: A retrospective toxicity study
- Thomas Herrmann, Michael Buhnerkempe, Morgan L. Wilson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?